Nevertheless, these studies targeted mouse PD-1 or PD-L1; few studies have reported chemotherapy-mediated combination therapy inhibiting the interaction between human PD-1 and PD-L1 therapeutic outcomes for CRC. The gene discussed is PDCD1; the disease is colorectal carcinoma.